Table 2.
Timing of Biomarker Test Order by Biomarker
| First Biomarker Test of Any Type Observed |
First EGFR Test Observed |
First ALK Test Observed |
First BRAF Test Observed |
First ROS1 Test Observed |
First KRAS Test Observed |
|
|---|---|---|---|---|---|---|
| Timing of Biomarker Test | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| No biomarker test observed | 1989 (11.4) | 2408 (13.7) | 2728 (15.6) | 7364 (42.0) | 4990 (28.5) | 7810 (44.6) |
| At least one biomarker test observed | 15,524 (88.6) | 15,105 (86.3) | 14,785 (84.4) | 10,149 (58.0) | 12,523 (71.5) | 9703 (55.4) |
| Before first-line therapya | 14,820 (95.5) | 14,289 (94.6) | 13,950 (94.4) | 8882 (87.5) | 11,488 (91.7) | 8380 (86.4) |
| From start of first-line therapy to before start of second linea | 350 (2.3) | 401 (2.7) | 403 (2.7) | 520 (5.1) | 447 (3.6) | 532 (5.5) |
| From start of second-line therapy to before start of third linea | 46 (0.3) | 51 (0.3) | 60 (0.4) | 157 (1.6) | 101 (0.8) | 145 (1.5) |
| From start of third-line therapy to before start of fourth linea | 11 (0.1) | 12 (0.1) | 20 (0.1) | 57 (0.6) | 42 (0.3) | 56 (0.6) |
| From start of fourth-line therapy to before start of fifth linea | 5 (0.0) | 6 (0.0) | 9 (0.1) | 32 (0.3) | 21 (0.2) | 27 (0.3) |
| From start of fifth-line therapy to before start of sixth linea | 1 (0.0) | 1 (0.0) | 1 (0.0) | 10 (0.1) | 5 (0.0) | 9 (0.1) |
| On or after start of sixth-line therapya | 291 (1.9) | 345 (2.3) | 342 (2.3) | 491 (4.8) | 419 (3.4) | 554 (5.7) |
a
The denominator is all patients receiving at least one biomarker test (in bold) for each column.